Innoviva Posts $73.9 Million Quarterly Loss As Armata Stake Drops, Even With U.S. Drug Sales Up 45%

Operating income rose to $42.2 million, but a $139.5 million swing in investment values pushed the bottom line negative.

Share
Innoviva Posts $73.9 Million Quarterly Loss As Armata Stake Drops, Even With U.S. Drug Sales Up 45%

Innoviva, which collects royalties on GSK respiratory drugs and sells hospital antibiotics, reported a $73.9 million third-quarter net loss, or $1.03 a share, as the value of its investments fell. The core business improved: U.S. net product sales rose 45% to $43.3 million from $29.9 million a year earlier, and operating income climbed 21.9% to $42.2 million, the company said in an 8-K filed Wednesday.

Paper losses swamp operating gains

Net unfavorable changes in the fair value of equity and long-term investments totaled $139.5 million, primarily from a decline in Armata Pharmaceuticals' stock price at quarter-end, the company said. A year earlier Innoviva earned $89.9 million in the same quarter.

At September 30, its strategic healthcare investments were valued at $535.5 million. That included $323.7 million in Armata, $179.9 million in other strategic equity and convertible debt investments, and $31.9 million held by ISP Fund.

Total revenue slipped 1.6% to $106.1 million from $107.8 million. Growth in U.S. product sales was partly offset by lower royalty revenue and the timing of inventory sales to partners outside the U.S. Gross royalty revenue from GSK held steady at $58.1 million.

Hospital drugs carry the growth

Innoviva Specialty Therapeutics, its critical care and infectious disease unit, drove the U.S. gain. GIAPREZA brought in $23.1 million, XACDURO $16.1 million and XERAVA $3.4 million. Total net product sales were $49.4 million, including $6.1 million outside the U.S.

Operating income benefited from the higher sales, partly offset by spending to expand commercial activity. CEO Pavel Raifeld said the unit is "on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales."

NUZOLVENCE, a single-dose oral antibiotic for uncomplicated gonorrhea, is now commercially available in the U.S. Early efforts are focused on market access, distribution and dispensing infrastructure.

Buybacks and a $581 million cash pile

Innoviva repurchased 1,226,948 shares for $26.3 million in the quarter under its $125 million buyback program. Since inception it has bought back 3,829,116 shares for $82.7 million.

Cash and equivalents stood at $581.4 million at quarter-end, and receivables totaled $102.1 million. For the first nine months, net income was $29.3 million, down from $107.0 million a year earlier.

Raifeld said the company is evaluating new opportunities to broaden its portfolio while continuing the buyback.

Sources